Maternal antimullerian hormone levels do not predict fetal aneuploidy

Abstract

Purpose To determine if diminished ovarian reserve (measured by maternal antimullerian hormone (AMH) levels), is associated with fetal aneuploidy (determined by prenatal karyotype). Methods This case-control study included 213 women with singleton pregnancies who underwent both serum aneuploidy screening and invasive prenatal diagnosis. 18 patients carrying an aneuploid fetus served as cases and the remaining 195 women with a euploid fetus were controls. Serum AMH was measured using two assays: AMHbc (Beckman-Coulter) and AMHdsl (Diagnostic Systems Laboratories). Karyotypes were determined by chorionic villus sampling or amniocentesis. Results AMHbc levels did not differ between women with an aneuploid fetus and women with a euploid fetus (p= 0.46) and did not predict aneuploidy (ROC Area=0.57). Additionally, AMHbc values declined significantly with advancing gestational age. Conclusions Maternal AMH does not appear to be a marker of fetal aneuploidy in ongoing pregnancies. Contrary to previous reports, we found a significant decline in maternal AMH levels with advancing gestational age.

Anti‐Müllerian hormone as a marker of abortion in the first trimester of spontaneous pregnancy

“…The observed high AMH levels might have been due to the fact that women with PCOS were not excluded from the study . By contrast, Plante et al . found that AMH levels did not differ between women with an aneuploid fetus and those with an euploid fetus; neither were they a predictor of aneuploidy.…”

“…The present study shows that not only low but also high serum found that AMH levels did not differ between women with an aneuploid fetus and those with an euploid fetus; neither were they a predictor of aneuploidy. However, Shim et al 2 assayed AMH levels before conception, whereas Plante et al 3 measured them during ongoing pregnancy.…”

“…2 At present, however, there are conflicting reports on the value of AMH as a potential marker of aneuploidy in the first trimester of pregnancy. 2,3 Further tests are thus recommended to either confirm or exclude AMH as a useful predictor of pathology in the early stages of pregnancy.…”

Role of Baseline Antral Follicle Count and Anti-Mullerian Hormone in Prediction of Cumulative Live Birth in the First In Vitro Fertilisation Cycle: A Retrospective Cohort Analysis

“…This may offset the potentially favourable implication of higher ovarian response in the fresh stimulated cycle. Embryo quality is another major issue, which seemingly cannot be predicted by either AMH or AFC, as illustrated by previously reported studies which revealed no consistent correlation between AMH and embryo morphology nor aneuploidy rate [22], [23], [24]. Hence all these parameters do not seem to have good prediction on the qualitative aspect of embryo competence.…”

Association of Abnormal Ovarian Reserve Parameters With a Higher Incidence of Aneuploid Blastocysts

“…13 There are conflicting data regarding whether compromised ovarian reserve may be associated with an increase in aneuploid pregnancies. [14][15][16][17][18] Comprehensive chromosomal screening is a validated means by which the entire complement of chromosomes within an embryo can be analyzed. [19][20][21] Clinical application of this approach after biopsy of blastocyst stage embryos results in extremely favorable live birth rates after transfer of euploid embryos.…”